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The antibody responses elicited by immunization of humans with vaccinia virus (VACV) strains
Lister, Dryvax and NYVAC have been determined and compared. Neutralizing antibodies against
intracellular mature virus (IMV) and extracellular enveloped virus (EEV), and binding antibody
titres (ELISA) against the EEV protein B5, the IMV proteins A27 and H3, and VACV-infected cell
lysate were measured. Lister and Dryvax induced broadly similar antibody titres, consistent with
the fact that these vaccines each protected against smallpox. In contrast, antibody titres induced
by NYVAC were significantly lower than those induced by both Lister and Dryvax. Moreover,
there were qualitative differences with NYVAC-immunized subjects failing to induce A27-specific
antibodies. These observations suggest that although NYVAC is a safer VACV strain, it does
not induce an optimal VACV-specific antibody response. However, NYVAC strains engineered to
express antigens from other pathogens remain promising candidate vaccines for immunization
against other diseases.
Variola virus (VARV), the causative agent of smallpox, was
eradicated in 1977 by widespread vaccination with vaccinia
virus (VACV) but without an adequate understanding of the
protective mechanisms (Fenner et al., 1988). The WHO
reference vaccine was a calf lymph preparation of VACV
strain Lister, although several other strains were used,
including NYCBH (Dryvax), EM-63 and Tian Tan (Fenner
et al., 1988). These vaccine preparations had imperfect safety
records and, consequently, with current concerns regarding
bioterrorism and revaccination (Smith & McFadden, 2002),
modern and safer vaccines are needed. With no means of
testing the efficacy of new vaccines clinically, comparative
studies with conventional vaccine strains are required
(Greenberg et al., 2005; Putz et al., 2006; Davies et al., 2008).
During the smallpox eradication campaign, several attenu-
atedVACVstrainswereproduced and tested, includingCVI-
78 (Rivers, 1931),modified vaccinia Ankara (MVA) (Mayr &
Munz, 1964) and LC16m8 (Hashizume et al., 1985), derived
from NYCBH, Ankara and Lister, respectively. Although
these strains were safer, their efficacy is uncertain because
vaccinees were not exposed to smallpox. VACV strain
NYVAC was developed as a vaccine vector by deletion of
18 ORFs from VACV strain Copenhagen (Tartaglia et al.,
1992). NYVAC also has potential as a safer smallpox vaccine
and because it is highly attenuated, while retaining good
immunogenicity (Tartaglia et al., 1992). NYVAC protected
mice against VACV challenge (Belyakov et al., 2003) and was
safeinimmunocompromisedmacaques(Edghill-Smithetal.,
2003) although protective longevity is uncertain (Ferrier-
Rembert et al., 2008). NYVAC was also used safely in clinical
trials(Konishietal.,1998;Ockenhouseetal.,1998;Bartetal.,
2008; Harari et al., 2008; McCormack et al., 2008) but its
efficacy against smallpox is unknown.
VACV morphogenesis generates two antigenically distinct
infectious forms of virion: the intracellular mature virus
(IMV) and the extracellular enveloped virus (EEV) (Smith
et al., 2002). IMV is surrounded by one membrane, whereas
EEV has a second membrane containing virus antigens
absent from IMV. Both IMV- and EEV-specific antibodies
(Abs) confer some protection, although EEV-specific Abs
are more important (Boulter & Appleyard, 1973; Law et al.,
2005), and both are long-lived after immunization/infection
(Hammarlund et al., 2003; Putz et al., 2005, 2006). In
humans, H3 (Davies et al., 2005; Putz et al., 2006) and A27
are targets of IMV-neutralizing Abs and B5 is the only target
of EEV-neutralizing Abs (Bell et al., 2004; Putz et al., 2006).
In animal models, immunization with each of these proteins
confers some protection (Lai et al.,1 9 9 1 ;H o o p e ret al.,
2000, 2003; Fogg et al., 2004; Hooper et al., 2004; Pulford
et al., 2004; Davies et al., 2005; Lustig et al., 2005; Heraud
et al., 2006; Xiao et al., 2007). A supplementary figure is available with the online version of this paper.
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antigens following immunization with VACV strain Lister
were established (Putz et al., 2006). Here, these benchmarks
were compared to responses elicited by another licensed
smallpox vaccine, Dryvax and the attenuated VACV strain,
NYVAC. Vaccines were compared by (i) IMV-specific
neutralizing Abs and (ii) ELISA against recombinant EEV
(B5) and IMV (A27 and H3) antigens and against VACV-
infected cell lysate (VACV). All methods have been described
previously (Putz et al.,2 0 0 6 ) .N e u t r a l i z i n gA bt i t r e s( N D 50,
serum dilution reducing the number of plaques by 50%)
were determined by plaque reduction neutralization (PRN)
of sucrose-gradient purified VACV strain Western Reserve
(WR) IMV. ELISAs used WR-infected cell lysate and WR
recombinant B5 and A27, expressed in mammalian CHO
cells and in Escherichia coli, respectively. Bacterially expressed
H3 was a gift from Huw Davies (UC Irvine, USA).
Ab responses following immunization with VACV strains
Lister and Dryvax were compared (Fig. 1). Lister serum
samples were available from naı ¨ve individuals (n513) and
revaccinees (n569) at days 0 and 21, 6 months and 1 year
post-vaccination (Auckland et al., 2005; Putz et al., 2006).
Sera from individuals immunized with Dryvax were from
both VACV-naı ¨ve participants (n524) and revaccinees
(n525) at day 0 and 30 days post-vaccination. Vaccine
comparisons at day 0 and ‘1 month’ (days 21 or 30) were
made for naı ¨ve and revaccinee groups independently by
Kruskal–Wallis test with Dunn’s multiple comparison
(Prism 3.0).
In general, Ab responses were both quantitatively and
qualitatively similar between Lister and Dryvax, in both
titres (Fig. 1) and targets (Supplementary Fig. S1 available
in JGV Online). No differences were observed against the
VACV cell lysate (Fig. 1). B5 responses were also similar
although, in revaccinees, levels were higher (P,0.05) after
immunization with Dryvax. Addition of ¡10 mg recom-
binant H3 and A27 to these sera, reduced IMV neutral-
ization partially, indicating that both antigens induced
neutralizing Abs in each vaccine (Supplementary Fig. S1).
As reported for Lister-induced responses (Putz et al., 2006),
depletion of B5 Abs completely abrogated, or very greatly
reduced, the EEV-neutralizing activity of Dryvax sera,
indicating that B5 is the only target of EEV-neutralizing
Abs in both vaccines (Supplementary Fig. S1).
However, some differences were observed in the kinetics of
responses to different antigens (Fig. 1). One month after
vaccination, H3 titres were lower in naı ¨ve individuals
immunized with Lister compared with Dryvax (P,0.001).
Only 46% of individuals seroconverted (defined as four-
fold increase in titre) against H3 after Lister vaccination,
whereas 100% seroconverted after Dryvax immunization.
This is consistent with recombinant H3 protein reducing
the neutralizing activity of Dryvax (Supplementary Fig. S1)
but not Lister sera. This may reflect strain- or time-
Fig. 1. Comparison of Ab responses elicited by Lister and Dryvax in naı ¨ve individuals (naı ¨ve) and in revaccinees (re-vac). B5-,
A27-, H3- and whole virus (VACV)-specific Ab ELISA end-point titres and IMV-specific neutralizing (ND50) Ab titres were
determined. Cut-off levels for seropositivity for each assay (dotted lines) and statistically significant differences between naı ¨ve
groups and between re-vac groups (*, P,0.05; ***, P,0.001) are depicted. Error bars represent 95% confidence intervals. ND,
Not determined.
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tions, Ab responses peak at about days 28–30 (Frey et al.,
2003; Greenberg et al., 2005). So at day 21, when the Lister
samples were collected, the H3 Abs may be submaximal,
whereas the Dryvax samples were collected nearer the time
of peak titres. Similarly, A27 responses were higher in naı ¨ve
individuals immunized with Dryvax compared with Lister
(P,0.001). Antigen variation is unlikely to explain these
differences because the proteins share 99 to 100% aa
identity between these VACV strains (www.poxvirus.org).
Interestingly, unlike other antigens, the A27 titres were not
significantly different in revaccinees compared with naı ¨ve
individuals after Lister and Dryvax vaccination. Following
revaccination, Abs peak at day 14 (Stienlauf et al., 1999;
Frey et al., 2003; Greenberg et al., 2005). Possibly in
revaccinees, by days 21 or 30, A27 Abs are already
declining, suggesting differing kinetics compared with
other antigens. Following Dryvax vaccination, IMV-
neutralizing Abs followed a similar pattern, with titres
being slightly lower, though not significantly, in revacci-
nees compared with naı ¨ve individuals. This was surprising
but it was reported previously that, 28 days after
immunization, IMV-neutralizing responses were not dif-
ferent between vaccination groups (Kennedy et al., 2004;
Greenberg et al., 2005; Treanor et al., 2006). In this study,
A27 binding Abs in Dryvax revaccinees correlated strongly
with neutralizing Abs (Spearman, r50.8090; P,0.0001),
more than with other antigens. In contrast, 21 days after
immunization with Lister, neutralizing Abs in revaccinees
correlated most strongly with VACV binding Abs
(Spearman r50.8599, P,0.0001) and only moderately
with individual antigens (Putz et al., 2006).
Ab responses to Lister and NYVAC were compared next
(Fig. 2). Sera were obtained from individuals immunized
with recombinant NYVAC encoding HIV-1 (Clade C) gag,
pol, env, nef [(Bart et al., 2008), EuroVacc 01 trial,
www.eurovacc.org].N a ı ¨ve participants (n57) and revacci-
nees (n57) were immunized at day 0 and week 4 and sera
were collectedat day 0, and atweeks 4, 8, 24and 48following
vaccination. The day 21 and 4 weeks samples from the Lister
andNYVACtrials,respectively,werecomparedas‘1 month’.
These same day 21 Lister samples were also compared to
Fig. 2. Comparison of binding Ab responses elicited by Lister and NYVAC in naı ¨ve individuals (naı ¨ve) and in revaccinees (re-
vac). Cut-off levels for seropositivity for each assay (dotted lines) and statistically significant differences between naı ¨ve groups
and between re-vac groups (*, P,0.05; **, P,0.01; ***, P,0.001) are depicted. Error bars represent 95% confidence
intervals.
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Naı ¨ve and revaccinee groups were compared independently
(Kruskal–Wallis test, Dunn’s multiple comparison). The
6 months and 24 weekssamplesand the1 yearand 48 weeks
samples were also compared. At these times only two
vaccines were studied, and naı ¨ve and revaccinee groups were
compared independently (Mann–Whitney U test).
The major differences between Lister and NYVAC were that
(i) NYVAC induced significantly lower levels of Abs and (ii)
NYVAC did not induce any A27-specific Abs. For A27, none
ofthe previouslynaı ¨veindividualswas seropositiveevenafter
two NYVAC doses. Some revaccinees were seropositive due
toresidualAbsfromprevioussmallpoxvaccination(s)butno
individuals exhibited increased levels of A27-specific Abs. In
addition, depletion of A27-specific Abs from participants
immunized twice with NYVAC had no effect on IMV
neutralization (Supplementary Fig. S1). These observations
are consistent with A27 not being expressed in NYVAC-
infected HeLa cells (Najera et al.,2 0 0 6 ) .T h i sd i f f e r e n c ei s
probably not due to antigen variation between VACV strains
because the A27 proteins from both viruses share 99% aa
identity (www.poxvirus.org).
In general, NYVAC elicited weaker responses than Lister
against both EEV (B5-ELISA) and IMV (VACV-ELISA) in all
individuals. After one dose of NYVAC, the geometric mean
increase in titres were 1.0- to 3.8-fold, whereas increases after
Lister vaccination were up to 17.1-fold. In addition, 4 of 14
individuals immunized with NYVAC did not seroconvert to
any of the antigens tested and only one individual
seroconverted against B5, H3 and VACV. In contrast, 70 of
72 individuals seroconverted after being immunized with
Lister. After two doses of NYVAC (2 months), B5 and VACV
responses were similar to Lister-induced responses. By 6 and
12 months, however, NYVAC-induced Abs declined to levels
below those induced by Lister. In addition, in revaccinees, the
second dose of NYVAC did not boost Ab titres. The fold
increase between 4 and 8 weeks in this group was only 1- to
1.7-fold, indicating that NYVAC demonstrates very limited
boosting efficacy in vaccinated individuals. If a protective Ab
level is greater than that induced 1 year after boosting with a
licensed vaccine (Lister re-vac) (Putz et al.,2 0 0 5 ) ,t h e n
NYVAC would not be deemed protective. These findings are
consistent with the observation that in mice, even after two
NYVAC immunizations, (i) neutralizing Ab levels were
significantly lower 150 days post-immunization compared
with Lister-induced levels, and (ii) long-term protection was
poorer following NYVAC immunization (Ferrier-Rembert
et al., 2008).
H3 responses after NYVAC vaccination were unusual.
Responses induced by two doses of NYVAC ¢ those
elicited by Lister in revaccinees or naı ¨ve individuals,
respectively (2 months, P,0.05). NYVAC-induced H3
responses were also maintained over 1 year to levels equal
to that in revaccinees immunized with Lister. Possibly, this
maintenance of H3-specific Abs may be influenced by the
lack of A27-specific Abs. NYVAC-induced H3-specific Abs
were compared to IMV PRN titres and a strong correlation
was found (Spearman, r50.8724, P,0.001); much stronger
than that for Lister samples. However, incubation of sera
with up to 10 mg recombinant H3, only reduced the
neutralizing capacity by a maximum of 15%
(Supplementary Fig. S1). This indicates that, even without
A27, other IMV-neutralizing targets must be present. This is
consistent with a recent study highlighting the flexibility and
redundancy in IMV-neutralizing Abs (Benhnia et al., 2008).
Followingvaccination withtwodosesof NYVAC (‘2 month’
samples), IMV-neutralizing Abs were surprisingly low. No
significant differences were observed between the VACV
ELISA titres induced by NYVAC and Lister but, in
revaccinees, NYVAC-induced neutralizing Ab levels were
significantly lower than Lister-induced titres (P,0.01, Fig.
3a). As such, even though VACV ELISA titres correlated
strongly with IMV PRN titres for both vaccines (Lister,
Spearman r50.8529, P,0.0001; NYVAC, Spearman
r50.7168, P50.0006), the lines of best fit provided different
equations (Fig. 3b). For a given VACV ELISA titre, the
Fig. 3. Comparison of binding and neutralizing Ab responses
elicited by Lister and NYVAC. (a) VACV-specific binding (VACV
ELISA) Ab levels and IMV-specific neutralizing (IMV PRN) Ab levels
detected at the ‘2 month’ time point after immunization with Lister or
NYVAC are compared. Responses in naı ¨ve individuals (naı ¨ve) and in
revaccinees (re-vac) are shown. Statistically significant differences
between naı ¨ve groups and between re-vac groups (**, P,0.01) are
depicted. Error bars represent 95% confidence intervals. (b)
Correlations between VACV-specific binding Ab titres and IMV-
specific neutralizing Ab titres for individuals immunized with Lister or
NYVAC. Lines of best fit are depicted.
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than that induced by Lister. This reflects the lack of an A27
response and/or differences in other neutralizing targets. For
example, in addition to A27 neither L1 nor A17 (two targets
of IMV-neutralizing Abs) are expressed in NYVAC-infected
HeLa cells (Najera et al., 2006). It is also possible that low
neutralizing Ab levels are elicited because the infection is
replication-deficient and new virions are not produced. This
finding demonstrates the importance of using functional
assays, such as neutralizing assays, to assess the efficacy of
new vaccine strains.
In summary, binding and neutralizing Ab levels following
immunization with VACV strains Lister, Dryvax and
NYVAC were determined and compared. In general,
Dryvax induced quantitatively and qualitatively similar
responses to Lister. Some antigen-specific Abs did differ in
magnitude but this probably reflects the times of sample
collection. The similarities between these two effective
vaccines provide some insight into the protective mechan-
isms involved. In contrast, NYVAC-induced Ab levels were
lower than those of Lister, even after two NYVAC
vaccinations. Similarly, MVA induced lower neutralizing
responses than Dryvax in naı ¨ve individuals, even after two
MVA vaccinations, but responses were similar in the short-
term in revaccinees (Parrino et al., 2007). In addition, no
qualitative differences were observed between MVA- and
Dryvax-induced Abs against neutralizing targets (Davies
et al., 2008). However, important qualitative differences
were detected here between NYVAC and Lister. These
differences render NYVAC an unlikely new smallpox
vaccine. Although safe for patients in whom smallpox
vaccination is contraindicated, NYVAC may not elicit
strong enough responses to be efficacious.
Our findings also suggest that kinetics of different antigen-
specific Abs may vary following infection and that this, in
turn, influences neutralizing Ab kinetics. In addition, with
different vaccine strains and as the time since vaccination
changes, although VACV-specific ELISA titres may correl-
ate with IMV-neutralizing titres, a certain ELISA titre will
not necessarily always correspond to a specific IMV-
neutralizing titre. These differences highlight the need for
independent neutralization analysis and the importance of
multiple correlates of immunity.
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